Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 17/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18045625 | 0.92 | WNT3A (0.50) | WNT3AMAPT | |
| SCHEMBL16098914 | 0.85 | WNT3A (0.60) | WNT3A | |
| SCHEMBL16098529 | 0.85 | WNT3A (0.57) | WNT3A | |
| SCHEMBL16098943 | 0.85 | WNT3A (0.57) | WNT3A | |
| SCHEMBL16098909 | 0.84 | WNT3A (0.58) | WNT3A | |
| SCHEMBL16097980 | 0.84 | ALDH1A1 (0.62) | WNT3AMAPT | |
| SCHEMBL16097991 | 0.81 | WNT3A (0.64) | WNT3A | |
| SCHEMBL20653086 | 0.78 | PTPN1 (0.67) | WNT3A | |
| SCHEMBL28207102 | 0.76 | PTPN1 (0.66) | WNT3A | |
| SCHEMBL16097943 | 0.76 | WNT3A (0.58) | WNT3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976327-B1 | 3-ACETYLAMINO-1-(PHENYL-HETEROARYL-AMINOCARBONYL OR PHENYL-HETEROARYL-CARBONYLAMINO)BENZENE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | Bayer Pharma AG (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-20160263122-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-15 | — | — | US | disclosed |
| WO-2014147021-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263122-A1 | NOVEL COMPOUNDS | NAT1, AADAC, CBR3 | WNT3A 3929/4885AURKB 1086/4885MAPT 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.